- Open Access
Indirect costs associated with out-of-country referral for proton therapy: a survey of adult and pediatric patients in Alberta, Canada
BMC Health Services Research volume 21, Article number: 683 (2021)
Patients in Alberta, Canada are referred to the United States (US) for proton treatment. The Alberta Ministry of Health pays for the proton treatment and the cost of flights to and from the United States. This study aimed to determine the out-of-pocket expenses incurred by patients or patients’ families.
An electronic survey was sent to 59 patients treated with proton therapy between January 2008 and September 2019. Survey questions asked about expenses related to travel to the US and those incurred while staying in the US, reimbursement of expenses, and whether any time away from work was paid or unpaid leave.
Seventeen respondents (response rate, 29%) reported expenses of flights for family members (mean, CAD 1886; range CAD 0–5627), passports/visas and other travel costs (mean, CAD 124; range CAD 0–546), accommodation during travel to the US (mean, CAD 50; range CAD 0–563), food during travel to the US (mean, CAD 89; range CAD 0–338), accommodation in the US (rented home/apartment mean, CAD 7394; range CAD 3075-13,305; hotel mean, CAD 4730; range CAD 3564-5895; other accommodation mean CAD 2660; range CAD 0–13,842), transportation in the US (car mean, CAD 2760; range CAD 0–7649; bus/subway mean, CAD 413; range CAD 246–580), and food in the US (mean, CAD 2443; range 0–6921). Expenses were partially reimbursed or covered by not-for-profit organizations or government agencies for some patients (35%). Patients missed a mean of 59 days of work; accompanying family members missed an average of 34 days. For 29% this time away from work was paid, but unpaid for 71% of respondents.
Multiple factors contributed to the expenses incurred including age of the patient, number of accompanying individuals, available accommodation, mode of transportation within the US, and whether the patient qualified for financial support. Added to this burden is the potential loss of wages for time away from work. The study showed a large variation in indirect costs for each family and supports actively seeking more opportunities for financial support for families with children with cancer.
Proton therapy provides potential dosimetric and clinical advantages over photon therapy for the treatment of children and adults with benign and malignant tumors. Proton therapy can achieve better normal tissue sparing, resulting in a reduction in adverse side effects [1, 2]. This is of particular value in children and adolescents whose developing organs are particularly susceptible to late effects, especially neurocognitive and cardiac dysfunctions, and secondary cancers . The adoption of proton therapy as a treatment option has occurred globally. There are 99 operating proton therapy facilities world-wide, 38 located in the United States (US) alone . Canada is the only G8 country without a proton facility . Canadians for whom proton therapy is recommended must be referred abroad.
The Alberta Ministry of Health covers the direct cost of proton therapy in the US for those who are approved for this treatment. This cost includes the proton treatment and associated treatments such as anesthesia and hospitalization, and concurrent chemotherapy. These costs are estimated to be $200,000 per patient, in Canadian dollars (CAD) . The cost of one return flight to and from the US for the patient, and in the case of pediatric and adolescent patients, one return flight for one parent or guardian are indirect costs covered by the Ministry of Health . However, all remaining expenses such as flights for additional family members, accommodation, food and transportation within the destination city are indirect costs not publicly covered and must be paid for by the patient or the patient’s family.
Iragorri et al. recently reported a systematic review including 105 studies of out-of-pocket costs faced by cancer patients and their caregivers . A cancer diagnosis was associated with high out-of-pocket expenses, accounting for 16% of the annual incomes of cancer patients and caregivers in high-income countries. Most out-of-pocket spending was for travel/transportation and caregiver costs, and the highest mean out-of-pocket costs were for pediatric patients and their caregivers. The authors concluded that opportunities exist within healthcare systems to improve coverage for these costs to ensure equitable access to care.
Evaluations of health care costs are often limited to those directly related to the cost of providing care to the patient. However, taking a societal perspective approach, the cost evaluation needs to be one which “accounts for benefits, harms, and costs to all parties” . Indirect costs are most often associated with opportunity costs from decreased productivity or lost income [10,11,12]. Productivity loss spans both paid and unpaid work and these costs are incurred by employers, patients, and the communities in which this work is normally performed. Being absent from paid work can result in lost income to patients, and to any family members providing supportive care which, when included in cost estimates, forms part of the cost of informal caregiving. Informal caregiving also includes the cost of the care given and caregiver time [10,11,12,13]. Ignoring indirect costs has the potential to provide an inaccurate measure of actual costs associated with health care . The requirement to travel away from home to receive medical treatment may not only require time away from work but will mean additional financial pressures on patients and their families to cover the costs for travel, lodging, food, and entertainment in the destination location . This is especially relevant for those who must travel to international destinations to access clinical infrastructure not available domestically.
This study aimed to determine the indirect costs associated with traveling from Alberta, Canada to the US for proton therapy. This included out-of-pocket expenses incurred by patients and/or families, and time costs for those who missed work during the proton treatment time frame.
This study used a descriptive survey method to gather expense-related data for the costs associated with traveling to and staying in the US during the treatment course. The study population was all patients referred for proton therapy from Alberta to outside of Canada, and who subsequently completed this treatment between January 2008 and September 2019. Excluded from this study were those who were referred for treatment abroad but who subsequently did not pursue this treatment option, those who have died since receiving the proton therapy, and those who had not yet completed their proton treatment course by the time of the survey. Ethics approval was obtained from the Health Research Ethics Board of Alberta.
A study invitation letter was mailed to each patient. Study participants were those who would have been responsible for the out-of-pocket expenses not covered by the provincial health plan. For the pediatric patients, the parent or guardian who accompanied the patient were the ones to whom participation was requested. Respondents were not offered any compensation or gifts for completing the survey. The survey was open from August 9, 2019 until September 30, 2019. Reminders to encourage survey participation or determine reason for noncompletion of the survey were not allowable within the ethics and operational approvals that stipulated that participants may not be contacted further beyond the initial request for survey participation to minimize potential for emotional distress within this vulnerable patient population.
An electronic survey was developed and conducted using REDCap, a secure web-based platform for collecting and managing data which is hosted and supported by the Women and Children’s Health Research Institute at the University of Alberta (Supplementary Appendix 1) . The web address for the survey was provided in the invitation letter.
At the start of the survey, participants were asked to provide the name of the patient and indicate if the person completing the survey was the patient or the parent or guardian of the patient. The first survey section consisted of nine questions related to travel to and from the US; mode of travel, who travelled, and the costs associated with this travel in Canadian dollars (CAD). The next section consisted of 10 questions pertaining to the stay within the US; length of stay, accommodation type and mode of transportation and the costs (in CAD) associated with each, food costs, and whether any of the costs were reimbursed and by whom. The survey concluded by asking if the patient or any accompanying family members missed work during this treatment time frame. Those who chose the affirmative were directed to indicate who missed work, how many days were missed, and whether this time away from work was paid or unpaid leave.
Descriptive statistics were reported for the study variables. Mean and range were reported for continuous variables. Frequency and proportions were reported for the categorical variables. All costs and benefits were adjusted for inflation to 2020 Canadian dollars and discounted 3% per annum. The data were presented in graphical form stratified by adults and children. SPSS version 25.0 (IBM Corp, Armonk, NY) was used to run the statistical analysis. No comparisons were made as the study was descriptive in nature.
Between January 2008 and September 2019, 74 patients were referred out-of-country for proton therapy. Patients who could not be found (n = 5), had not yet completed proton therapy at the time of the survey (n = 4), died before the time of the survey (n = 4), and decline proton therapy referral (n = 2) were excluded. Deaths occurred secondary to an accident (n = 1) or disease recurrence (n = 3), all of who had been diagnosed with medulloblastoma and died between two and 4 years after proton therapy. Fifty-nine included patients received the invitation letter. One patient requested a paper copy of the survey which was subsequently completed and returned. A total of seventeen surveys were completed with a response rate of 29%. Respondents were 8/23 adult patients (35% response rate) and parents of 9/36 pediatric patients (25% response rate) treated with proton therapy.
Table 1 lists the demographic, disease, and treatment characteristics of the patients. All patients were referred to the US for proton therapy. The majority (94%) of the respondents traveled to the US by airplane. One individual travelled by plane for the treatment consultation but by car for the treatment course. Travel time by air was 1 day and 4 days by car, respectively. Four respondents made separate trips to the US for the consultation and treatments. All patients were accompanied by one or more family members or other individuals (Fig. 1C). One young adult patient (age, < 30 years) was accompanied by both parents. Two adult patients brought their children, as young as 8 months of age, to the US during their proton therapy. Two pediatric patients were accompanied by both parents, one of whom also was accompanied by a sibling. Other accompanying individuals included children and a friend.
For all respondents, accommodations during this stay for consultation and/or treatment were in a rented home/apartment (53%), hotel (18%), hospital accommodations (12%), or other (29%). Other accommodations described included the Ronald McDonald House in Jacksonville, Florida and the AstraZeneca Hope Lodge in Boston, Massachusetts (Fig. 1A). Among respondents, the mode of transportation to the proton center for daily treatment was by car (47%), hospital shuttle (29%), on foot (29%), taxi (18%), bus or subway (12%). Six respondents used greater than one mode of transportation (Fig. 1B).
Costs to travel
Fifty-nine percent of respondents reported having to cover the costs for additional plane tickets for travel to and from the US. Additional airfare was purchased for an average of 1.8 accompanying individuals. For the individual who drove, the cost for car fuel was CAD 715. Table 2 outlines the travel costs for adult versus pediatric patients.
Payment for passports before traveling was reported by 35% of those surveyed. For these respondents, the median number of passports obtained by each family was 2 (range 1–4). One respondent reported an additional cost to have their passports expedited. One respondent was required to obtain US Visas, with a stated cost of CAD 500. Obtaining medical insurance was listed as an additional travel cost by 24% of those surveyed. For each of these respondents, insurance was purchased for the patient and their accompanying family. One respondent indicated that the patient’s work benefits covered the first 60 days of travel. Only 2 days of additional insurance was purchased.
Costs during stay in the US
Out-of-pocket costs incurred by patients and their families during their stay in the US for proton therapy are listed in Table 2. Most respondents (53%) rented a home or apartment for the duration of their time in the US. The cost of this accommodation varied greatly irrespective of the city and duration of stay in the US. Those who rented a home or apartment incurred a mean cost of CAD 7394 (range, CAD 3075-13,305). Hotel expenses averaged CAD 4730 (range, CAD 3564-5895). Those who were fortunate to stay in hospital accommodations incurred no expense for accommodation and had reduced food expenses.
Multiple comments from respondents referred to Boston as an expensive city which impacted their ability to find affordable housing. However, others who qualified for housing support in Boston were less impacted by the city’s cost of living. Respondent comments relating to their US accommodation costs are included in Table 3.
Those who were required to drive to the proton center for the daily treatments incurred the greatest transportation expenses with a mean cost of CAD 2760 (range, CAD 0–7649). The cost for bus transportation was reported as CAD 200 by one respondent. A combination of bus and subway was reported by another as costing CAD 500. Another respondent reported a taxi cost of CAD10 per day. Those who were able to walk or take a hospital shuttle incurred no cost.
Food expenses during their stay in the US reported costs that ranged from CAD 0–6921with an average of CAD 2443. Those who stayed in hospital accommodations incurred the lowest expense with one respondent reporting no expense for food except for a meal during travel to the US. Expenses in other categories of expenses (telephone, internet, laundry, non-treatment-related transportation, and entertainment) were not measured in this study but respondents provided comments on these costs without providing expense data (Table 3).
Transportation to the US was reimbursed wholly for all patients and, for pediatric patients, one parent by the Ministry of Health. For accompanying family, including the second parent for pediatric patients, only one patient (6%), an adult, reported partial reimbursement by Revenue Canada. Partial or total reimbursement was reported by both adult patients and caregivers of pediatric patients for accommodation, transportation, and food during the stay in the US. One adult patient (13%) reported partial reimbursement by Revenue Canada for these items. For caregivers of pediatric patients, 56% reported partial or total reimbursement of these costs either by the Kids with Cancer Society (KWCS), a regional philanthropic organization, or Family Support for Children with Disabilities (FSCD), a public agency. In total, a mean of CAD 602/patient was reported as reimbursed (adult patients, CAD 174/patient; caregivers of pediatric patients, CAD 982/patient) which accounts for 5.3% of the total out-of-pocket costs paid by patients or their families.
It was indicated by 82% of the respondents that the patient, patient’s spouse, parents, siblings, or other individuals were required to miss work during this treatment period. Other individuals were reported to be grandparents by one respondent (Fig. 1).
For the 38% of adult patients who missed work, a mean of 59 days of work was missed (range 45–75 days). Compared to adult patients who missed work, a greater proportion of spouses of these adult patients (50%) and parents of pediatric patients (mothers, 67%; fathers, 56%) missed work (Fig. 1D). For accompanying individuals, a mean of 34 days of work was missed (range 5–55 days). This time away from work was paid, including use of banked vacation time, for 29% of these individuals, and unpaid for 71% (Fig. 2). One respondent commented that once paid vacation was used up the remaining time away was without pay. Comments regarding the impact from being away from work and general comments are listed in Table 3.
This study surveyed indirect (out-of-pocket) costs borne by patients and their families for out-of-country referral to receive proton therapy for up to 3 months away from their homes. Our findings show a high variability of out-of-pocket expenses and inadequate reimbursement across the study population. Out-of-pocket expenses included costs for flights for family members, passports, visas, accommodation during travel to the US, accommodation and transportation within the US, and food. These are expenses not paid for or reimbursed by the Alberta Ministry of Health, which limits coverage to direct costs including the proton therapy, concurrent therapies, and flight for the patient and, for children, one parent or guardian. The financial burden of these expenses may limit some patients to seek such treatment and highlights the importance of supporting patients and their families through the out-of-country referral process.
A recent systematic review of out-of-pocket expenses of cancer patients and their caregivers suggested a need for comprehensive costing data for different cancer sites and treatment modalities to inform healthcare systems planning and decision making . Travel/transportation was identified as the highest component of out-of-pocket expenses in Canada, Australia, and Western Europe, consistent with our findings for patients referred for proton therapy. Out-of-pocket costs for travel/transportation was higher in countries with universal healthcare coverage, such as Canada, compared with the US in the review ($205 vs. $66 in US dollars [USD]). In our study, travel costs were very high due the long distances to the proton therapy facilities in the US of approximately 2400 to 4300 km. Iragorri et al. found that the highest mean out-of-pocket costs were for pediatric patients due to longer, resource-intensive therapy and costly survivorship care . Our study, however, focused only on assessment of costs for proton therapy rather than overall cancer therapy and survivorship care. Although delivery of proton therapy and supportive care needs are often more complex for pediatric patients, [5, 6] our study demonstrated little difference between out-of-pocket costs for caregivers of pediatric patients and adult patients (CAD 202/day vs. CAD 187/day). Overall treatment time was shorter for pediatric compared to adult patients (median number of fractions, 30 vs. 37 fractions; median length of stay in US, 56 vs. 65 days) such that overall out-of-pocket costs for caregivers of pediatric patients and adult patients was similar (CAD 10,672 vs. CAD 11,348).
Additional factors played a role in the differing costs incurred by adult patients and caregivers of pediatric patients. There was a bias towards referral of adult and pediatric patients to specific proton facilities despite all of but one of the proton facilities being capable of treating patients of all ages. Adult patients were more likely to stay at a hotel associated with higher out-of-pocket expense for accommodation in the US for treatment. Caregivers of pediatric patients had higher out-of-pocket expenses for daily transportation in the US while adult patients were more likely to walk or take the bus/subway to the treatment facility. Despite these differences, out-of-pocket expenses were similar for adult patients and caregivers of pediatric patients although differences could have effect on patient satisfaction which was not measured in the present study. The number of individuals accompanying the patient to the US for proton therapy duration varied across respondents due to age of patient and family circumstances. The most likely person to accompany the patient, and subsequently miss work, was the spouse of adult patients and mothers of pediatric patients. While 38% of the adult patients in this study reported missing work, the impact was greater on spouses who accompanied adult patients and parents of pediatric patients. While the survey captured those designated as the primary accompanying support individuals, it was clear there were other visitors including children and friends of adult patients who also provided support during this time who may have incurred out-of-pocket expenses that were not included in our dataset.
Additional costs to travel included costs of passports for those who did not already have passports, and for visas for one patient and parent. Canadian residents without Canadian citizenship may be required to obtain a non-immigrant visitor visa in order to enter the US. The cost for a US visitor visa is currently USD 160 . Inability to fund the application for a passport or visa can limit patients with low socioeconomic status from accessing proton therapy.
Reimbursement of costs
Financial support was available for families of pediatric patients to cover some of the costs. The KWCS is a not-for-profit organization committed to providing direct support for children with cancer and their families, both inside and outside of the hospital setting, and funds for research that improves the well-being and outcomes for children with cancer . FSCD is a provincial government program providing a variety of support for families coping with a child’s illness or disability who meet certain eligibility criteria . However, not all families reported receiving support from KWCS or FSCD. It is unclear if any expenses were covered directly instead of by reimbursing families, and therefore were not reported as out-of-pocket expenses. Despite this, the study did highlight the greater availability of financial support for families of children with cancer. On the other hand, adult patients do not appear to have similar support. Two adult respondents did qualify for hospital housing which reduced the financial burden significantly compared to the other adult respondents. For medical services provided outside of Canada, the Canadian Revenue Agency allows Canadians to claim the travel-related expenses. For those who qualify, accommodation, meals and transportation expenses may be reimbursed .
Limitations of the study
This study was limited by a sample size, survey completion rate, and retrospective design, which relies on respondent memory and approximated expense amounts. Despite these limitations, this study provides the largest dataset on indirect costs of proton therapy referral to date. Costs were reported in CAD by respondents. Currency conversion at time of expense was not factored into these cost estimates but it is recognized that the value of the CAD compared to the USD can play a large role in cost burden to Canadian patients. While this study did not ask about or provide total indirect costs incurred by each patient and their families, it did demonstrate the financial impact of traveling to the US for cancer treatment. Each family faced different circumstances which resulted in a large variation of costs incurred.
The value of this study is in the broad understanding of the financial experience for families traveling to the US for treatment. It provides essential background for future prospective studies which can more closely examine the resources, supports and costs involved in out-of-country cancer care. In order to improve support provided to these patients, future research should determine actual non-reimbursed costs, and analyze who is qualifying for expense reimbursement or upfront financial support to assess the impact of socioeconomic status and race . To determine the actual cost of sending patients to the US for proton therapy, future research would need to tally the direct treatment costs and all indirect costs including costs incurred by patients, the provincial government, and charitable organizations, and from lost productivity.
Should Canada develop one or more local proton therapy facility in future decades, these facilities would be based in major metropolitan areas in proximity to large academic hospitals. This would require many patients and their families from elsewhere in Canada to travel for up to 3 months and incur out-of-pocket expenses in similar categories to the present study. Previous modelling supports the viability of one proton therapy facility in Western Canada (population, 11.1 million), for example, and require > 75% of the population of this region of Canada to travel for proton therapy treatment to the metropolitan area where the facility is developed, regardless of which metropolitan area within this region is chosen for development . Given the large geographic area of Canada, barriers to accessing radiation therapy have been reported in many areas [23,24,25]. Out-of-pocket expenses associated with referral to a Canadian proton therapy facility will need study when feasible.
Canada currently has no proton treatment facility, necessitating some patients to travel to the US for this specialized treatment. While the direct cost of the treatment is paid for by the Ministry of Health, there are many indirect costs related to traveling to and staying in the US which are incurred by patients and their families. This study determined the variable costs incurred and the financial support available to some but not all of these families and highlighted the financial impact of traveling to the US for cancer treatment. Determining the true cost of sending Alberta patients to the US for proton treatment requires consideration of both the direct and indirect costs, including the cost of lost productivity for those unable to work during this treatment time. Consistent with a recent systematic review of out-of-pocket expenses of cancer patients and their families,  our data indicate that out-of-pocket costs associated with referral for proton therapy are substantial and support a role of healthcare systems in assisting patients to ensure equitable access to care.
Availability of data and materials
The survey dataset generated during the current study will not be publicly available to protect the privacy of the participants and their responses. Aggregate data generated for analysis is available from the corresponding author on reasonable request.
Baumann B, Mitra N, Harton J, Xiao Y, Wojcieszynski A, Gabriel P, et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. Jama Oncol. 2020;6(2):237–46. https://doi.org/10.1001/jamaoncol.2019.4889.
Boehling N, Grosshans D, Bluett J, Palmer M, Song X, Amos R. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys. 2012;82(2):643–52. https://doi.org/10.1016/j.ijrobp.2010.11.027.
Mohan R, Grosshans D. Proton therapy – present and future. Adv Drug Deliv Rev. 2017;109:26–44. https://doi.org/10.1016/j.addr.2016.11.006.
Particle Therapy Co-Operative Group [Web page]. Particle Therapy Facilities in Operation. Available at: http://www.ptcog.ch/index.php/facilities-in-operation. Accessed 4 Dec 2020.
Tsang D, Patel S. Proton beam for cancer. Can Med Assoc J. 2019;191(24):E664–6. https://doi.org/10.1503/cmaj.190008.
Patel S, Kostaras X, Parliament M, Olivotto IA, Nordel R, Aronyk K, et al. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? Curr Oncol. 2014;21(5):251–62. https://doi.org/10.3747/co.21.2207.
Alberta Government [Web page]. Out of country health services funding requests. Available at: https://www.alberta.ca/ahcip-out-of-country-health-funding.aspx. Accessed 25 Jan 2021.
Iragorri N, de Oliveira C, Fitzgerald N, Essue B. The out-of-pocket cost burden of cancer care—a systematic literature review. Curr Oncol. 2021;28(2):1216–48. https://doi.org/10.3390/curroncol28020117.
Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276(14):1172–7. https://doi.org/10.1001/jama.1996.03540140060028.
Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17(1):28–40. https://doi.org/10.1038/s41585-019-0258-3.
Undabeitia J, Torres-Bayona S, Sampron N, Arrazola M, Bollar A, Armendariz M, et al. Indirect costs associated with glioblastoma: experience of one hospital. Neurologia. 2018;33(2):85–91. https://doi.org/10.1016/j.nrl.2016.05.003.
Ernst R. Indirect costs and cost effectiveness analysis. Value Health. 2006;9(4):253–61. https://doi.org/10.1111/j.1524-4733.2006.00114.x.
Joo H, George M, Fang J, Wang G. A literature review of indirect costs associated with stroke. J Stroke Cerebrovasc Dis. 2014;23(7):1753–63. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.02.017.
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. PharmacoEconomics. 2014;32(4):335–44. https://doi.org/10.1007/s40273-014-0132-3.
Suzana M, Mills A, Tangcharoensathien V, Chongsuvivatwong V. The economic burden of medical treatment: a cross sectional study of Maldivian medical travelers. BMC Health Serv Res. 2015;15:418. https://doi.org/10.1186/s12913-015-1054-2.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. https://doi.org/10.1016/j.jbi.2008.08.010.
US Department of State Bureau of Consular Affairs [Web page]. Fees for visa services. Available at: https://travel.state.gov/content/travel/en/us-visas/visa-information-resources/fees/fees-visa-services.html#temp. Accessed 29 Oct 2020.
Kids with Cancer [Web page]. What we do. Available from: https://www.kidswithcancer.ca/what-we-do/. Accessed 30 Jun 2020.
Alberta Government [Web page]. Family Support for Children with Disabilities. Available from: https://www.alberta.ca/fscd.aspx. Accessed 25 Jun 2020.
Government of Canada [Web page]. Medical Expenses 2019. Available at: https://www.canada.ca/en/revenue-agency/services/forms-publications/publications/rc4065/medical-expenses.html. Accessed 30 Oct 2020.
Tsang DS, Schulte F. Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship. Neuro Oncol. 2021;23(7):1050–51. https://doi.org/10.1093/neuonc/noab079.
Smith WL, Smith CD, Patel S, et al. What conditions make proton beam therapy financially viable in Western Canada? Cureus. 2018;10(11):e3644. https://doi.org/10.7759/cureus.3644.
Gillan C, Briggs K, Pazos A, et al. Barriers to accessing radiation therapy in Canada: a systematic review. Radiat Oncol. 2012;7(1):167–75. https://doi.org/10.1186/1748-717X-7-167.
Liu E, Santibanez P, Puterman M, et al. A quantitative analysis of the relationship between radiation therapy use and travel time. Int J Radiat Oncol Biol Phys. 2015;93(3):710–8. https://doi.org/10.1016/j.ijrobp.2015.06.004.
Santibanez P, Gaudet M, French J, Liu E, Tyldesley S. Optimal location of radiation therapy centers with respect to geographic access. Int J Radiat Oncol Biol Phys. 2014;89(4):745–55. https://doi.org/10.1016/j.ijrobp.2014.04.011.
This study was unfunded.
Ethics approval and consent to participate
Ethics approval was obtained from the Health Research Ethics Board of Alberta-Cancer Committee (HREBA.CC-18-0590). The introductory cover letter and survey were reviewed and approved by the ethics committee. The ethics committee approved a waiver of consent for this minimal risk study. All methods were carried out in accordance with relevant guidelines and regulations.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Middleton, J., Black, K., Ghosh, S. et al. Indirect costs associated with out-of-country referral for proton therapy: a survey of adult and pediatric patients in Alberta, Canada. BMC Health Serv Res 21, 683 (2021). https://doi.org/10.1186/s12913-021-06701-z
- Proton therapy
- Out-of-country medical care
- Indirect costs